Kazuki Koiwai

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

Rimei Nishimura, Yuko Tanaka, Kazuki Koiwai et al. · Cardiovascular Diabetology · 2015 · 104 citations · Full text

Medicine, Endocrinology, Pharmacology +15

Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

Takashi Kadowaki, Masakazu Haneda, Nobuya Inagaki et al. · Advances in Therapy · 2014 · 86 citations

Medicine, Pharmacology, Pharmacotherapy +13

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

Akiko Sarashina, Kazuki Koiwai, Leo Seman et al. · Drug Metabolism and Pharmacokinetics · 2012 · 86 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Long‐term treatment with empagliflozin as add‐on to oral antidiabetes therapy in <scp>J</scp> apanese patients with type 2 diabetes mellitus

Eiichi Araki, Yukio Tanizawa, Yuko Tanaka et al. · Diabetes Obesity and Metabolism · 2015 · 67 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

Takashi Kadowaki, Masakazu Haneda, Nobuya Inagaki et al. · Advances in Therapy · 2015 · 45 citations

Medicine, Pharmacology, Pharmacotherapy +15